The Mays Cancer Center at UT Health San Antonio and Evestra Inc., a San Antonio-based biopharmaceutical company, have been awarded a five-year, $3.3 million Academic Industry Partnership grant from NIH for the research and development of a drug targeting ovarian cancer, EC359. It is the first grant of this kind awarded to The University of Texas Health Science Center at San Antonio.
EC granted marketing authorization for Elahere (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens. Elahere is the first and only folate receptor alpha-directed antibody drug conjugate medicine approved in the EU, as well as Iceland, Liechtenstein, Norway, and Northern Ireland.
